nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—L-Phenylalanine—TAT—liver cancer	0.0538	0.791	CrCbGaD
Lisdexamfetamine—Blood pressure increased—Sorafenib—liver cancer	0.0231	0.0306	CcSEcCtD
Lisdexamfetamine—Cardiomyopathy—Epirubicin—liver cancer	0.0167	0.0221	CcSEcCtD
Lisdexamfetamine—Cardiomyopathy—Doxorubicin—liver cancer	0.0155	0.0205	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Sorafenib—liver cancer	0.0153	0.0203	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.0151	0.02	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Sorafenib—liver cancer	0.0134	0.0177	CcSEcCtD
Lisdexamfetamine—Weight decreased—Sorafenib—liver cancer	0.0131	0.0174	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.0128	0.017	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Sorafenib—liver cancer	0.0128	0.0169	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Sorafenib—liver cancer	0.0127	0.0168	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Sorafenib—liver cancer	0.0122	0.0162	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Sorafenib—liver cancer	0.011	0.0145	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Sorafenib—liver cancer	0.0108	0.0143	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Sorafenib—liver cancer	0.0105	0.0139	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Sorafenib—liver cancer	0.0105	0.0139	CcSEcCtD
Lisdexamfetamine—Mental disorder—Sorafenib—liver cancer	0.0102	0.0135	CcSEcCtD
Lisdexamfetamine—Malnutrition—Sorafenib—liver cancer	0.0101	0.0134	CcSEcCtD
Lisdexamfetamine—Angioedema—Sorafenib—liver cancer	0.00924	0.0122	CcSEcCtD
Lisdexamfetamine—Dyskinesia—Epirubicin—liver cancer	0.0091	0.012	CcSEcCtD
Lisdexamfetamine—Hypertension—Sorafenib—liver cancer	0.00873	0.0116	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00855	0.0113	CcSEcCtD
Lisdexamfetamine—Dry mouth—Sorafenib—liver cancer	0.00842	0.0111	CcSEcCtD
Lisdexamfetamine—Dyskinesia—Doxorubicin—liver cancer	0.00842	0.0111	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Sorafenib—liver cancer	0.00825	0.0109	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Sorafenib—liver cancer	0.00809	0.0107	CcSEcCtD
Lisdexamfetamine—Skin disorder—Sorafenib—liver cancer	0.00802	0.0106	CcSEcCtD
Lisdexamfetamine—Anorexia—Sorafenib—liver cancer	0.00787	0.0104	CcSEcCtD
Lisdexamfetamine—Selegiline—CYP2E1—liver cancer	0.00753	0.111	CrCbGaD
Lisdexamfetamine—Dyspnoea—Sorafenib—liver cancer	0.00736	0.00974	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Sorafenib—liver cancer	0.00726	0.00962	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Sorafenib—liver cancer	0.00717	0.0095	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Sorafenib—liver cancer	0.00712	0.00943	CcSEcCtD
Lisdexamfetamine—Fatigue—Sorafenib—liver cancer	0.00711	0.00942	CcSEcCtD
Lisdexamfetamine—Constipation—Sorafenib—liver cancer	0.00706	0.00934	CcSEcCtD
Lisdexamfetamine—Phenelzine—CYP2E1—liver cancer	0.00664	0.0977	CrCbGaD
Lisdexamfetamine—Urticaria—Sorafenib—liver cancer	0.00656	0.00868	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Sorafenib—liver cancer	0.00652	0.00864	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Epirubicin—liver cancer	0.00633	0.00838	CcSEcCtD
Lisdexamfetamine—Diplopia—Epirubicin—liver cancer	0.00621	0.00822	CcSEcCtD
Lisdexamfetamine—Affect lability—Epirubicin—liver cancer	0.00611	0.00809	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Sorafenib—liver cancer	0.00608	0.00805	CcSEcCtD
Lisdexamfetamine—Asthenia—Sorafenib—liver cancer	0.00592	0.00784	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Doxorubicin—liver cancer	0.00586	0.00776	CcSEcCtD
Lisdexamfetamine—Diplopia—Doxorubicin—liver cancer	0.00574	0.0076	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Epirubicin—liver cancer	0.00567	0.0075	CcSEcCtD
Lisdexamfetamine—Affect lability—Doxorubicin—liver cancer	0.00565	0.00748	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Sorafenib—liver cancer	0.00565	0.00748	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00559	0.0074	CcSEcCtD
Lisdexamfetamine—Dizziness—Sorafenib—liver cancer	0.00546	0.00723	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A2—liver cancer	0.00527	0.0298	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Sorafenib—liver cancer	0.00525	0.00695	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Doxorubicin—liver cancer	0.00524	0.00694	CcSEcCtD
Lisdexamfetamine—Rash—Sorafenib—liver cancer	0.0052	0.00689	CcSEcCtD
Lisdexamfetamine—Dermatitis—Sorafenib—liver cancer	0.0052	0.00688	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00517	0.00685	CcSEcCtD
Lisdexamfetamine—Headache—Sorafenib—liver cancer	0.00517	0.00685	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC40A1—liver cancer	0.00503	0.0285	CbGpPWpGaD
Lisdexamfetamine—Nausea—Sorafenib—liver cancer	0.0049	0.00649	CcSEcCtD
Lisdexamfetamine—Weight increased—Epirubicin—liver cancer	0.00488	0.00646	CcSEcCtD
Lisdexamfetamine—Weight decreased—Epirubicin—liver cancer	0.00485	0.00642	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00474	0.00628	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Epirubicin—liver cancer	0.00452	0.00599	CcSEcCtD
Lisdexamfetamine—Weight increased—Doxorubicin—liver cancer	0.00452	0.00598	CcSEcCtD
Lisdexamfetamine—Weight decreased—Doxorubicin—liver cancer	0.00449	0.00594	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.00439	0.00581	CcSEcCtD
Lisdexamfetamine—Hepatitis—Epirubicin—liver cancer	0.00429	0.00568	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Doxorubicin—liver cancer	0.00418	0.00554	CcSEcCtD
Lisdexamfetamine—Visual impairment—Epirubicin—liver cancer	0.00414	0.00548	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Epirubicin—liver cancer	0.00406	0.00537	CcSEcCtD
Lisdexamfetamine—Eye disorder—Epirubicin—liver cancer	0.00401	0.00531	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Epirubicin—liver cancer	0.00398	0.00528	CcSEcCtD
Lisdexamfetamine—Hepatitis—Doxorubicin—liver cancer	0.00397	0.00526	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Epirubicin—liver cancer	0.00388	0.00513	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Epirubicin—liver cancer	0.00387	0.00512	CcSEcCtD
Lisdexamfetamine—Visual impairment—Doxorubicin—liver cancer	0.00383	0.00507	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—DNAJB1—liver cancer	0.00379	0.0214	CbGpPWpGaD
Lisdexamfetamine—Mental disorder—Epirubicin—liver cancer	0.00376	0.00498	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Doxorubicin—liver cancer	0.00376	0.00497	CcSEcCtD
Lisdexamfetamine—Malnutrition—Epirubicin—liver cancer	0.00374	0.00495	CcSEcCtD
Lisdexamfetamine—Eye disorder—Doxorubicin—liver cancer	0.00371	0.00491	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Doxorubicin—liver cancer	0.00369	0.00488	CcSEcCtD
Lisdexamfetamine—Nervousness—Epirubicin—liver cancer	0.00363	0.00481	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Doxorubicin—liver cancer	0.00359	0.00475	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Doxorubicin—liver cancer	0.00358	0.00474	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A2—liver cancer	0.00355	0.0201	CbGpPWpGaD
Lisdexamfetamine—Vision blurred—Epirubicin—liver cancer	0.00352	0.00466	CcSEcCtD
Lisdexamfetamine—Mental disorder—Doxorubicin—liver cancer	0.00348	0.00461	CcSEcCtD
Lisdexamfetamine—Malnutrition—Doxorubicin—liver cancer	0.00346	0.00458	CcSEcCtD
Lisdexamfetamine—Agitation—Epirubicin—liver cancer	0.00343	0.00455	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC40A1—liver cancer	0.00339	0.0192	CbGpPWpGaD
Lisdexamfetamine—Nervousness—Doxorubicin—liver cancer	0.00336	0.00445	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—DNAJB1—liver cancer	0.00336	0.019	CbGpPWpGaD
Lisdexamfetamine—Palpitations—Epirubicin—liver cancer	0.0033	0.00437	CcSEcCtD
Lisdexamfetamine—Vision blurred—Doxorubicin—liver cancer	0.00326	0.00431	CcSEcCtD
Lisdexamfetamine—Convulsion—Epirubicin—liver cancer	0.00324	0.00429	CcSEcCtD
Lisdexamfetamine—Hypertension—Epirubicin—liver cancer	0.00323	0.00427	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—CPT1B—liver cancer	0.00323	0.0182	CbGpPWpGaD
Lisdexamfetamine—Agitation—Doxorubicin—liver cancer	0.00318	0.00421	CcSEcCtD
Lisdexamfetamine—Anxiety—Epirubicin—liver cancer	0.00317	0.0042	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00316	0.00418	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A2—liver cancer	0.00314	0.0178	CbGpPWpGaD
Lisdexamfetamine—Dry mouth—Epirubicin—liver cancer	0.00311	0.00412	CcSEcCtD
Lisdexamfetamine—Palpitations—Doxorubicin—liver cancer	0.00306	0.00405	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Epirubicin—liver cancer	0.00305	0.00404	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC40A1—liver cancer	0.003	0.017	CbGpPWpGaD
Lisdexamfetamine—Convulsion—Doxorubicin—liver cancer	0.003	0.00397	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Epirubicin—liver cancer	0.00299	0.00396	CcSEcCtD
Lisdexamfetamine—Hypertension—Doxorubicin—liver cancer	0.00299	0.00395	CcSEcCtD
Lisdexamfetamine—Tachycardia—Epirubicin—liver cancer	0.00298	0.00394	CcSEcCtD
Lisdexamfetamine—Skin disorder—Epirubicin—liver cancer	0.00296	0.00392	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Epirubicin—liver cancer	0.00295	0.0039	CcSEcCtD
Lisdexamfetamine—Anxiety—Doxorubicin—liver cancer	0.00293	0.00388	CcSEcCtD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—CYCS—liver cancer	0.00293	0.0166	CbGpPWpGaD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00292	0.00387	CcSEcCtD
Lisdexamfetamine—Anorexia—Epirubicin—liver cancer	0.00291	0.00385	CcSEcCtD
Lisdexamfetamine—Dry mouth—Doxorubicin—liver cancer	0.00288	0.00381	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Doxorubicin—liver cancer	0.00282	0.00374	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Doxorubicin—liver cancer	0.00277	0.00366	CcSEcCtD
Lisdexamfetamine—Insomnia—Epirubicin—liver cancer	0.00276	0.00365	CcSEcCtD
Lisdexamfetamine—Tachycardia—Doxorubicin—liver cancer	0.00275	0.00365	CcSEcCtD
Lisdexamfetamine—Skin disorder—Doxorubicin—liver cancer	0.00274	0.00363	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Doxorubicin—liver cancer	0.00273	0.00361	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Epirubicin—liver cancer	0.00272	0.0036	CcSEcCtD
Lisdexamfetamine—Somnolence—Epirubicin—liver cancer	0.00271	0.00359	CcSEcCtD
Lisdexamfetamine—Anorexia—Doxorubicin—liver cancer	0.00269	0.00356	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Epirubicin—liver cancer	0.00268	0.00355	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—GLUL—liver cancer	0.00265	0.015	CbGpPWpGaD
Lisdexamfetamine—Decreased appetite—Epirubicin—liver cancer	0.00265	0.00351	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Epirubicin—liver cancer	0.00263	0.00349	CcSEcCtD
Lisdexamfetamine—Fatigue—Epirubicin—liver cancer	0.00263	0.00348	CcSEcCtD
Lisdexamfetamine—Constipation—Epirubicin—liver cancer	0.00261	0.00345	CcSEcCtD
Lisdexamfetamine—Insomnia—Doxorubicin—liver cancer	0.00255	0.00338	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Doxorubicin—liver cancer	0.00252	0.00333	CcSEcCtD
Lisdexamfetamine—Somnolence—Doxorubicin—liver cancer	0.00251	0.00332	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Doxorubicin—liver cancer	0.00248	0.00329	CcSEcCtD
Lisdexamfetamine—SLC6A2—Monoamine Transport—MAPK14—liver cancer	0.00246	0.0139	CbGpPWpGaD
Lisdexamfetamine—Decreased appetite—Doxorubicin—liver cancer	0.00245	0.00325	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00244	0.00323	CcSEcCtD
Lisdexamfetamine—Fatigue—Doxorubicin—liver cancer	0.00243	0.00322	CcSEcCtD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—TRIO—liver cancer	0.00243	0.0138	CbGpPWpGaD
Lisdexamfetamine—Urticaria—Epirubicin—liver cancer	0.00242	0.00321	CcSEcCtD
Lisdexamfetamine—Constipation—Doxorubicin—liver cancer	0.00241	0.0032	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Epirubicin—liver cancer	0.00241	0.00319	CcSEcCtD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.0024	0.0136	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00238	0.0135	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00238	0.0135	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.00229	0.0129	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Epirubicin—liver cancer	0.00225	0.00298	CcSEcCtD
Lisdexamfetamine—Urticaria—Doxorubicin—liver cancer	0.00224	0.00297	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Doxorubicin—liver cancer	0.00223	0.00295	CcSEcCtD
Lisdexamfetamine—Asthenia—Epirubicin—liver cancer	0.00219	0.0029	CcSEcCtD
Lisdexamfetamine—SLC6A3—Monoamine Transport—MAPK14—liver cancer	0.00218	0.0123	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTA3—liver cancer	0.00218	0.0123	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—HNF4A—liver cancer	0.00212	0.012	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—STAT3—liver cancer	0.00212	0.012	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Epirubicin—liver cancer	0.00209	0.00276	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Doxorubicin—liver cancer	0.00208	0.00275	CcSEcCtD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—GJB1—liver cancer	0.00205	0.0116	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—GLUL—liver cancer	0.00203	0.0115	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Doxorubicin—liver cancer	0.00202	0.00268	CcSEcCtD
Lisdexamfetamine—Dizziness—Epirubicin—liver cancer	0.00202	0.00267	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTA4—liver cancer	0.00199	0.0113	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—TGFB1—liver cancer	0.00196	0.0111	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTA2—liver cancer	0.00194	0.011	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Epirubicin—liver cancer	0.00194	0.00257	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Doxorubicin—liver cancer	0.00193	0.00256	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTA3—liver cancer	0.00193	0.0109	CbGpPWpGaD
Lisdexamfetamine—Rash—Epirubicin—liver cancer	0.00192	0.00255	CcSEcCtD
Lisdexamfetamine—Dermatitis—Epirubicin—liver cancer	0.00192	0.00254	CcSEcCtD
Lisdexamfetamine—Headache—Epirubicin—liver cancer	0.00191	0.00253	CcSEcCtD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—MAPK14—liver cancer	0.0019	0.0108	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTA1—liver cancer	0.00187	0.0106	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Doxorubicin—liver cancer	0.00187	0.00247	CcSEcCtD
Lisdexamfetamine—Nausea—Epirubicin—liver cancer	0.00181	0.0024	CcSEcCtD
Lisdexamfetamine—Vomiting—Doxorubicin—liver cancer	0.00179	0.00238	CcSEcCtD
Lisdexamfetamine—Rash—Doxorubicin—liver cancer	0.00178	0.00236	CcSEcCtD
Lisdexamfetamine—Dermatitis—Doxorubicin—liver cancer	0.00178	0.00235	CcSEcCtD
Lisdexamfetamine—Headache—Doxorubicin—liver cancer	0.00177	0.00234	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTA4—liver cancer	0.00176	0.00997	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTA2—liver cancer	0.00172	0.00972	CbGpPWpGaD
Lisdexamfetamine—Nausea—Doxorubicin—liver cancer	0.00168	0.00222	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTA1—liver cancer	0.00166	0.00938	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—NFE2L2—liver cancer	0.00165	0.00933	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.00161	0.00912	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.0016	0.00906	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—MYO5B—liver cancer	0.0016	0.00906	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—GLUL—liver cancer	0.00158	0.00894	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GPX3—liver cancer	0.00157	0.0089	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFA—liver cancer	0.00157	0.0089	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SERPINA1—liver cancer	0.00155	0.00877	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.00154	0.0087	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—PRKCE—liver cancer	0.00152	0.00862	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—NFE2L2—liver cancer	0.00146	0.00826	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.00143	0.00808	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.00142	0.00802	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—MYO5B—liver cancer	0.00142	0.00802	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFA—liver cancer	0.00139	0.00788	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GPX3—liver cancer	0.00139	0.00788	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SERPINA1—liver cancer	0.00137	0.00777	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.00136	0.00771	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—liver cancer	0.00126	0.00714	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—CASP3—liver cancer	0.00124	0.00703	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00122	0.00689	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—GLUL—liver cancer	0.00121	0.00685	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TNF—liver cancer	0.00117	0.00662	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—TRIO—liver cancer	0.00117	0.00662	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—liver cancer	0.00117	0.00662	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00116	0.00657	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00111	0.0063	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00111	0.0063	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GGT1—liver cancer	0.00111	0.00626	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—NR1H4—liver cancer	0.00105	0.00596	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—TRIO—liver cancer	0.00105	0.00592	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TNF—liver cancer	0.00104	0.00587	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTP1—liver cancer	0.000994	0.00562	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—HMOX1—liver cancer	0.000981	0.00555	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GGT1—liver cancer	0.000981	0.00555	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CG—liver cancer	0.000954	0.00539	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTM1—liver cancer	0.000914	0.00517	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—HGF—liver cancer	0.000914	0.00517	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP2—liver cancer	0.000897	0.00508	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTP1—liver cancer	0.000881	0.00498	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—HMOX1—liver cancer	0.000869	0.00491	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.000868	0.00491	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CD—liver cancer	0.000838	0.00474	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.00082	0.00464	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTM1—liver cancer	0.000809	0.00458	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—HGF—liver cancer	0.000809	0.00458	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000782	0.00442	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—PIK3CB—liver cancer	0.000776	0.00439	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—PRKCE—liver cancer	0.000775	0.00439	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ANXA2—liver cancer	0.00075	0.00424	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ATP7B—liver cancer	0.00075	0.00424	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.000744	0.00421	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—BRAF—liver cancer	0.000737	0.00417	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CB—liver cancer	0.000731	0.00413	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—MTOR—liver cancer	0.000731	0.00413	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000726	0.00411	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CASP3—liver cancer	0.000714	0.00404	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000709	0.00401	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—JUN—liver cancer	0.000693	0.00392	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000693	0.00392	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP9—liver cancer	0.000674	0.00381	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000664	0.00376	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000664	0.00376	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PRKCE—liver cancer	0.000646	0.00366	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—CDKN1A—liver cancer	0.000633	0.00358	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000628	0.00355	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—RAF1—liver cancer	0.000615	0.00348	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCE—liver cancer	0.000578	0.00327	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CCR4—liver cancer	0.000566	0.0032	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—BRAF—liver cancer	0.000565	0.00319	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—liver cancer	0.000551	0.00312	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—CYCS—liver cancer	0.000537	0.00304	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—RAF1—liver cancer	0.000471	0.00267	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000467	0.00264	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—F2—liver cancer	0.000449	0.00254	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CA—liver cancer	0.000445	0.00252	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—BRAF—liver cancer	0.000439	0.00248	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—HRAS—liver cancer	0.000438	0.00248	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CHN2—liver cancer	0.000431	0.00244	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—liver cancer	0.000431	0.00244	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—liver cancer	0.000417	0.00236	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—F2—liver cancer	0.000401	0.00227	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IFT88—liver cancer	0.000394	0.00223	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—AKT1—liver cancer	0.000386	0.00219	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—PPARA—liver cancer	0.000377	0.00213	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFB1—liver cancer	0.000372	0.00211	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—liver cancer	0.000371	0.0021	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—RAF1—liver cancer	0.000367	0.00207	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT1—liver cancer	0.000364	0.00206	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—CYCS—liver cancer	0.000361	0.00204	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—liver cancer	0.000339	0.00192	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—BRAF—liver cancer	0.000337	0.0019	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—TRIO—liver cancer	0.000334	0.00189	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFB1—liver cancer	0.00033	0.00187	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—liver cancer	0.000329	0.00186	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—CYCS—liver cancer	0.00032	0.00181	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CCR4—liver cancer	0.00032	0.00181	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000314	0.00178	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—TRIO—liver cancer	0.000303	0.00171	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—liver cancer	0.000301	0.00171	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.000297	0.00168	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CCR4—liver cancer	0.000291	0.00164	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—RAF1—liver cancer	0.000281	0.00159	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ALB—liver cancer	0.00028	0.00159	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000278	0.00157	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—HRAS—liver cancer	0.00026	0.00147	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—PPARA—liver cancer	0.000254	0.00144	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—RAF1—liver cancer	0.000253	0.00143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SHC3—liver cancer	0.000242	0.00137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—F2—liver cancer	0.000226	0.00128	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—PPARA—liver cancer	0.000225	0.00127	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—liver cancer	0.000202	0.00114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—liver cancer	0.000201	0.00113	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	0.000195	0.0011	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ALB—liver cancer	0.000189	0.00107	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FST—liver cancer	0.000188	0.00106	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PRKCE—liver cancer	0.000184	0.00104	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	0.000179	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TRIO—liver cancer	0.000179	0.00101	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCR4—liver cancer	0.000172	0.000971	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—RAF1—liver cancer	0.000171	0.000965	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKCE—liver cancer	0.000167	0.000946	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ALB—liver cancer	0.000167	0.000945	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	0.000166	0.000939	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CSF2—liver cancer	0.000163	0.000922	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	0.000159	0.000899	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—HRAS—liver cancer	0.000155	0.000875	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—RAF1—liver cancer	0.000151	0.000855	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CSF2—liver cancer	0.000148	0.000837	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADAM17—liver cancer	0.000136	0.000768	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—F2—liver cancer	0.000128	0.000723	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PSMA4—liver cancer	0.000128	0.000722	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PSMD10—liver cancer	0.000128	0.000722	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CG—liver cancer	0.000122	0.000692	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—F2—liver cancer	0.000116	0.000657	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CG—liver cancer	0.000111	0.000629	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CD—liver cancer	0.000108	0.000609	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCE—liver cancer	9.88e-05	0.000559	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CD—liver cancer	9.77e-05	0.000553	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CB—liver cancer	9.38e-05	0.000531	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF2—liver cancer	9.36e-05	0.00053	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CSF2—liver cancer	8.74e-05	0.000495	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RAF1—liver cancer	8.72e-05	0.000493	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—H2AFX—liver cancer	8.62e-05	0.000487	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL2—liver cancer	8.61e-05	0.000487	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CB—liver cancer	8.52e-05	0.000482	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL2—liver cancer	7.82e-05	0.000442	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TERT—liver cancer	7.79e-05	0.000441	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KDR—liver cancer	7.13e-05	0.000403	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK14—liver cancer	7.08e-05	0.000401	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ESR1—liver cancer	6.95e-05	0.000393	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—F2—liver cancer	6.86e-05	0.000388	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CG—liver cancer	6.57e-05	0.000371	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APC—liver cancer	6.57e-05	0.000371	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BRAF—liver cancer	6.17e-05	0.000349	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CD—liver cancer	5.77e-05	0.000327	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CA—liver cancer	5.72e-05	0.000323	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SERPINE1—liver cancer	5.71e-05	0.000323	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KRAS—liver cancer	5.65e-05	0.00032	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CA—liver cancer	5.19e-05	0.000294	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RAF1—liver cancer	5.15e-05	0.000291	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MTOR—liver cancer	5.03e-05	0.000285	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CB—liver cancer	5.03e-05	0.000285	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRAS—liver cancer	4.8e-05	0.000272	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1B—liver cancer	4.72e-05	0.000267	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT1—liver cancer	4.67e-05	0.000264	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP3—liver cancer	4.63e-05	0.000262	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL2—liver cancer	4.62e-05	0.000261	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—liver cancer	4.6e-05	0.00026	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCND1—liver cancer	4.5e-05	0.000255	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JUN—liver cancer	4.49e-05	0.000254	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CTNNB1—liver cancer	4.46e-05	0.000252	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—liver cancer	4.37e-05	0.000247	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1A—liver cancer	4.36e-05	0.000246	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK8—liver cancer	4.25e-05	0.000241	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT1—liver cancer	4.24e-05	0.00024	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—liver cancer	3.93e-05	0.000222	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT3—liver cancer	3.89e-05	0.00022	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—liver cancer	3.61e-05	0.000204	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TGFB1—liver cancer	3.6e-05	0.000204	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KRAS—liver cancer	3.34e-05	0.000189	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CA—liver cancer	3.07e-05	0.000173	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—liver cancer	2.97e-05	0.000168	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRAS—liver cancer	2.84e-05	0.000161	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—liver cancer	2.72e-05	0.000154	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT1—liver cancer	2.51e-05	0.000142	CbGpPWpGaD
